Background
Genentech sells pirfenidone (Esbriet®), a drug approved to treat idiopathic pulmonary fibrosis (IPF), a serious progressive lung disease. Sandoz filed an Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of pirfenidone. Under the Hatch-Waxman Act, Sandoz’s ANDA filing triggered a patent infringement dispute before any product actually reached market.
Genentech asserted two categories of method patents: so-called Liver Function Test (LFT) patents, which cover methods of monitoring patients’ liver enzymes and adjusting pirfenidone dosing when abnormalities arise; and Drug-Drug Interaction (DDI) patents, covering methods of managing interactions between pirfenidone and other drugs. Genentech argued that Sandoz’s proposed label for its generic would cause physicians to practice these patented methods, making Sandoz liable for induced infringement under 35 U.S.C. § 271(b). The district court found for Sandoz, and Genentech appealed.
The Court’s Holding
The Federal Circuit affirmed on all counts. On the LFT patents, the court upheld the district court’s finding that those patents were invalid as obvious over the prior art — liver monitoring is a well-established practice for drugs with potential hepatotoxicity, and the specific monitoring protocols claimed in Genentech’s patents were predictable extensions of existing clinical practice. Because the patents were invalid, no infringement analysis was necessary for those claims.
On the DDI patents, the court affirmed the finding of no induced infringement. Induced infringement of a method patent requires proof that the defendant’s label or conduct will cause third parties (here, physicians) to perform the patented method. The court held that Sandoz’s proposed label did not actively encourage the specific patented drug-interaction management steps. Importantly, the court reaffirmed that courts must consider all relevant evidence — including the label, physician practice, and market realities — in assessing whether a generic label will induce infringement; the inquiry is not limited to the four corners of the proposed label.
Key Takeaways
- A generic drug manufacturer is not liable for induced infringement of a method patent if its proposed label does not affirmatively encourage physicians to perform the claimed method, even if some physicians will use the drug in ways that happen to infringe.
- Obviousness analysis for pharmaceutical method patents must account for established clinical practice in the relevant therapeutic area — well-known monitoring protocols cannot simply be claimed as patentable innovations.
- In Hatch-Waxman induced infringement disputes, courts may look beyond the proposed label to consider how physicians actually practice and whether the generic product would realistically be used in an infringing manner.
- Patent owners asserting method-of-treatment patents against generic drug entrants must show a tight connection between the proposed label’s instructions and the patented method.
Why It Matters
The intersection of patent law and pharmaceutical regulation continues to generate complex litigation over which generic drug labels trigger induced infringement liability. This case reinforces an important limitation on method patent enforcement: a generic manufacturer is not an insurer against all uses of its product that might infringe — it must be shown to actively promote the infringing use. For brand-name manufacturers, this makes it harder to block generic entry using method patents unless the patented method is specifically called out in the prescribing information.
The obviousness ruling on the liver monitoring patents also serves as a reminder that clinical monitoring protocols — while medically important — often do not meet the patent law bar for novelty and non-obviousness. Routine safety monitoring requirements built into FDA labeling will typically reflect standard clinical practice rather than inventive contributions, and courts will scrutinize such claims carefully.